Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy
De Luca et al. on behalf of EuroCoord aimed to derive a refined genotypic interpretation score (GIS) for darunavir based on virological response in patients harbouring subtype B HIV-1, and to validate its performance for non-B HIV-1 subtypes. The main finding was that a model including the new weighted score was more accurate in predicting the virological response at 8 weeks compared with three popular existing GISs for darunavir. Surprisingly, the model also outperformed GIS prediction of virological outcome in an independent validation set of non-B subtypes.
In conclusion, this score may be used for predicting response to darunavir in individuals failing previous protease inhibitors with different subtypes and thus be of help in designing the most appropriate salvage regimens.